COMPUGEN LTDCGENEarnings & Financial Report
Nasdaq · biotechnology
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big compan...
CGEN Q1 2024 Key Financial Metrics
营收
$2.6M
毛利润
$457.0K
营业利润
N/A
净利润
$7.3M
毛利率
17.9%
营业利润率
N/A
净利率
284.0%
同比增长
N/A
资金流向
COMPUGEN LTD Q1 2024 Financial Summary
COMPUGEN LTD reported revenue of $2.6M for Q1 2024, with a net profit of $7.3M (284.0% margin). Cost of goods sold was $2.1M.
Key Financial Metrics
| Total Revenue | $2.6M |
|---|---|
| Net Profit | $7.3M |
| Gross Margin | 17.9% |
| Operating Margin | N/A |
| Report Period | Q1 2024 |
利润表
| Q1 2024 | |
|---|---|
| 营收 | $2.6M |
| 同比增长 | N/A |
资产负债表
| Q1 2024 | |
|---|---|
| 总资产 | $121.3M |
| 总负债 | $55.8M |
| 股东权益 | $65.6M |
现金流量表
No data available for this period